Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
Real-time Quote. Real-time CHI-X - 04/24 08:25:02 am
79.69 CHF   +2.27%
06:16aAMGEN : Novartis shares rise as Swiss drugmaker lifts 2019 profit outlook
RE
06:07aNOVARTIS : Earnings Bolster CEO's Revamp Efforts--Update
DJ
05:48aNOVARTIS : 1Q Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations
The feature you requested does not exist. However, we suggest the following feature:

Amgen : Novartis shares rise as Swiss drugmaker lifts 2019 profit outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/24/2019 | 06:16am EDT
FILE PHOTO: Switzerland's national flag flies in front of the logo of Swiss drugmaker Novartis in Basel

ZURICH (Reuters) - Swiss drugmaker Novartis raised its 2019 profit target on Wednesday, striking an upbeat tone over a legal fight with peer and partner Amgen and on the safety of a key gene therapy that could win approval next month.

Its shares rose 2.8 percent by 0837 GMT.

Chief Executive Vas Narasimhan said he now sees 2019 core operating income growing at a high-single-digit percentage rate, up from the previous forecast of mid- to high-single-digit percentage growth. Sales are seen growing at the mid-single-digit rate, helped by heart failure drug Entresto and psoriasis medicine Cosentyx.

Cosentyx is Novartis's top seller after first-quarter sales rose 41 percent to $791 million (£612 million), while Entresto sales jumped 85 percent to $357 million.

"Taken together, we're really well positioned for growth," Narasimhan told reporters on a call.

Two additional pillars of Narasimhan's growth plans are Zolgensma, the gene therapy for rare spinal muscular atrophy (SMA), and Aimovig, the migraine drug on which Novartis has partnered with Amgen.

Asked about two deaths of babies in Zolgensma trials, including one in Europe in January that investigators deemed "possibly related to treatment", Narasimhan said he did not anticipate an impact on the timing of the U.S. Food and Drug Administration approval decision, due by May 31.

The baby may have had pneumonia when it received a Zolgensma infusion, he said, and was diagnosed with five separate viral infections before dying of respiratory sepsis.

"When you can't definitively prove one thing or another, the investigator is required to say there could be a potential contribution" from Zolgensma, Narasimhan said. "That does not mean the investigational agent actually contributed."

A U.S. drug review group this month recommended Zolgensma should be priced below the $4-5 million level Novartis has pegged as the gene therapy's value.

"We'll of course take that into consideration," Narasimhan said of the still-undisclosed price tag.

LEGAL HEADACHE

The 43-year-old Harvard-trained doctor said he is looking forward to taking on the Amgen dispute in court after the U.S. biotech sought to terminate the companies' partnership on Aimovig, a potential blockbuster, this year.

The dispute centres on Novartis's Sandoz unit's contract manufacturing deal with Alder Biopharmaceuticals to help produce an Aimovig rival, eptinezumab, which on Tuesday was accepted for FDA review.

"We hope to come to some sort of conclusion with respect to this in the coming years," Narasimhan said. "But in the meantime, it's business as usual."

Novartis reported first-quarter core net income rose 13 percent to $2.81 billion, compared to the $2.76 billion average estimate in a poll.

Sales excluding eyecare business Alcon, spun off to shareholders this month, rose 7 percent to $11.1 billion, compared to the $10.9 billion poll average.

(Reporting by John Miller; Editing by Michael Shields and Alexandra Hudson)

By John Miller

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
06:16aAMGEN : Novartis shares rise as Swiss drugmaker lifts 2019 profit outlook
RE
06:07aNOVARTIS : Earnings Bolster CEO's Revamp Efforts--Update
DJ
05:48aNOVARTIS : 1Q Earnings Snapshot
AQ
03:52aNovartis Shares Buoyed by Guidance Hike -- Update
DJ
01:35aNOVARTIS : Sales Rose in 1Q
DJ
01:01aNOVARTIS : starts 2019 with strong sales and double digit core operating income ..
AQ
04/23Global Stocks Weaken as Oil Prices Climb
DJ
04/18NOVARTIS : FDA accepts Novartiss BLA for brolucizumab for treatment of wet AMD
AQ
04/17NOVARTIS : AveXis data reinforce effectiveness of Zolgensma in treating spinal m..
AQ
04/17NOVARTIS : announces FDA filing acceptance and Priority Review of brolucizumab (..
AQ
More news
Financials ($)
Sales 2019 49 547 M
EBIT 2019 12 924 M
Net income 2019 8 537 M
Debt 2019 14 000 M
Yield 2019 3,83%
P/E ratio 2019 19,72
P/E ratio 2020 17,76
EV / Sales 2019 4,23x
EV / Sales 2020 4,00x
Capitalization 196 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 89,5 $
Spread / Average Target 17%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Srikant T. Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS4.88%195 750
JOHNSON & JOHNSON6.80%372 522
ROCHE HOLDING LTD.10.11%227 132
PFIZER-9.69%218 852
MERCK AND COMPANY-2.37%192 697
ELI LILLY AND COMPANY1.53%121 698